TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37312104

Group type: EXPERIMENTAL
Intervention: Outpatient computed tomography coronary angiography (CTCA) plus standard of care
Number of subjects: 2270

Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 2270
Study: 37312118

Group type: EXPERIMENTAL
Intervention: Multidisciplinary collaborative team combined with palliative care model
Number of subjects: 84

Group type: COMPARATOR
Intervention: Routine nursing intervention
Number of subjects: 84
Study: 37312127

Group type: EXPERIMENTAL
Intervention: Nano X CBCT scans
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional CBCT scans
Number of subjects: 30
Study: 37312140

Group type: EXPERIMENTAL
Intervention: Zhineng Qigong intervention (12-week training with face-to-face group activities and individual training)
Number of subjects: 52
Study: 37312165

Group type: EXPERIMENTAL
Intervention: 2 cycles of neoadjuvant CAPOX (oxaliplatin 130 mg/m2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4 cycles of neoadjuvant CAPOX (oxaliplatin 130 mg/m2)
Number of subjects: 0
Study: 37312222

Group type: EXPERIMENTAL
Intervention: Patient Pathway Pharmacist intervention
Number of subjects: 108

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 108
Study: 37312233

Group type: EXPERIMENTAL
Intervention: Mepolizumab (300 mg subcutaneously every 4 weeks)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 37312251

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37312287

Group type: EXPERIMENTAL
Intervention: Atrial flow regulator (AFR) implantation
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Atrial flow regulator (AFR) implantation in HFpEF patients
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Atrial flow regulator (AFR) implantation in HFrEF patients
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: HF-related deaths in HFrEF subgroup
Number of subjects: 87
Study: 37312582

Group type: EXPERIMENTAL
Intervention: My Sleep Our Sleep (MSOS) intervention
Number of subjects: 0
Study: 37312666

Group type: EXPERIMENTAL
Intervention: Behavioural counselling intervention to increase moderate-to-vigorous-intensity physical activity (MVPA) and decrease sedentary-time (SED-time)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 300
Study: 37313367

Group type: EXPERIMENTAL
Intervention: Uncontrolled asthma (ACQ-5 score > 1.5)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Symptoms of anxiety (HADS-A score > 7)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Symptoms of depression (HADS-D score > 7)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Mean HADS-A score
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Mean HADS-D score
Number of subjects: 109
Study: 37313403

Group type: EXPERIMENTAL
Intervention: Toripalimab plus chemotherapy (TC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone (PC)
Number of subjects: 0
Study: 37313851

Group type: EXPERIMENTAL
Intervention: Deuterium oxide ingestion before and after rupture
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control samples (not specified)
Number of subjects: 18
Study: 37313946

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 86
Study: 37314061

Group type: COMPARATOR
Intervention: Intravitreal lampalizumab (monthly)
Number of subjects: 4052

Group type: COMPARATOR
Intervention: Intravitreal lampalizumab (every-other-month)
Number of subjects: 4052

Group type: COMPARATOR
Intervention: Intravitreal pegcetacoplan (monthly)
Number of subjects: 4052

Group type: COMPARATOR
Intervention: Intravitreal pegcetacoplan (every-other-month)
Number of subjects: 4052

Group type: COMPARATOR
Intervention: Intravitreal avacincaptad pegol (monthly, 2 mg)
Number of subjects: 4052

Group type: COMPARATOR
Intervention: Intravitreal avacincaptad pegol (monthly, 4 mg)
Number of subjects: 4052
Study: 37314165

Group type: EXPERIMENTAL
Intervention: Idarucizumab (specific dabigatran reversal agent)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Andexanet alfa (for Xa inhibitors apixaban and rivaroxaban)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrate (PCC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard approaches for managing DOAC-treated patients requiring emergency surgery
Number of subjects: 0
Study: 37314197

Group type: EXPERIMENTAL
Intervention: Bone morphogenetic protein 10 (BMP10) plasma concentrations
Number of subjects: 1112

Group type: EXPERIMENTAL
Intervention: Log-transformed BMP10 concentration
Number of subjects: 1112

Group type: EXPERIMENTAL
Intervention: Log-transformed BMP10 concentration after multivariable adjustment
Number of subjects: 1112

Group type: EXPERIMENTAL
Intervention: BMP10 quartiles
Number of subjects: 1112
Study: 37314235

Group type: EXPERIMENTAL
Intervention: Population health care (usual care plus assessment via portal)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Usual care (assessment during triage at visits)
Number of subjects: 175
Study: 37314244

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 g bolus before hospital admission, followed by 1 g infusion over 8 hours)
Number of subjects: 1310

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1310

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 1310
Study: 37314275

Group type: EXPERIMENTAL
Intervention: Family-based treatment
Number of subjects: 452

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 452
Study: 37314323

Group type: EXPERIMENTAL
Intervention: tUEFMA (remote version of UEFMA)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: tUEFMA
Number of subjects: 22
Study: 37314435

Group type: EXPERIMENTAL
Intervention: New paediatric VO2max Z-score reference equations
Number of subjects: 344

Group type: COMPARATOR
Intervention: Cooper's weight- and height-based linear equations
Number of subjects: 344
Study: 37314501

Group type: EXPERIMENTAL
Intervention: Neratinib 160 mg daily with trametinib 1 mg, 5 days on and 2 days off
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Neratinib 160 mg daily with trametinib 1 mg daily (DL1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pharmacokinetic analysis
Number of subjects: 20
Study: 37314530

Group type: EXPERIMENTAL
Intervention: Intravenous administration of ketone tracer (R)-[1-
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral administration of ketone tracer (R)-[1-
Number of subjects: 0
Study: 37314665

Group type: EXPERIMENTAL
Intervention: Subcutaneous abatacept 125 mg once weekly
Number of subjects: 0
Study: 37314797

Group type: EXPERIMENTAL
Intervention: Multistrain probiotic (8 billion colony-forming units per day) for 8 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 50
Study: 37314839

Group type: EXPERIMENTAL
Intervention: Behavior Change Techniques (BCTs) including goal-setting, self-monitoring, feedback, and action planning, each delivered for 2 weeks over a total of 10 weeks.
Number of subjects: 60
Study: 37314844

Group type: EXPERIMENTAL
Intervention: Economic empowerment intervention
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Focus group discussions (FGDs) with adolescents and youths living with HIV
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Cross-sectional survey
Number of subjects: 200

Group type: COMPARATOR
Intervention: Randomized controlled trial
Number of subjects: 200
Study: 37314845

Group type: EXPERIMENTAL
Intervention: Sedentary Behavior Reduction in Pregnancy Intervention (SPRING)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 53
Study: 37314850

Group type: EXPERIMENTAL
Intervention: Health Circuit (adaptive case management approach)
Number of subjects: 204
Study: 37315062

Group type: EXPERIMENTAL
Intervention: Statin withdrawal
Number of subjects: 61
Study: 37315099

Group type: EXPERIMENTAL
Intervention: Intolerance-of-uncertainty therapy (IUT)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Metacognitive therapy (MCT)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Both IUT and MCT
Number of subjects: 64
Study: 37315114

Group type: EXPERIMENTAL
Intervention: Tivozanib
Number of subjects: 46
Study: 37315119

Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 52911

Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 52911
Study: 37315225

Group type: EXPERIMENTAL
Intervention: Ibrutinib plus venetoclax
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Any treatment
Number of subjects: 0
Study: 37315261

Group type: EXPERIMENTAL
Intervention: Selpercatinib
Number of subjects: 8
Study: 37315265

Group type: EXPERIMENTAL
Intervention: Pertuzumab plus Trastuzumab (P + T)
Number of subjects: 28
Study: 37315268

Group type: EXPERIMENTAL
Intervention: Daratumumab, low-dose cyclophosphamide, lenalidomide, bortezomib, and dexamethasone (Dara-CVRd)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide, or lenalidomide, dexamethasone, and cyclophosphamide (MyeXI treatment)
Number of subjects: 103
Study: 37315297

Group type: EXPERIMENTAL
Intervention: COMBO (EBRT + BT)
Number of subjects: 579

Group type: COMPARATOR
Intervention: BT alone
Number of subjects: 579
Study: 37315325

Group type: EXPERIMENTAL
Intervention: CAPTURE intervention
Number of subjects: 0
Study: 37315558

Group type: EXPERIMENTAL
Intervention: Single intramuscular GRAd-COV2 administration
Number of subjects: 917

Group type: EXPERIMENTAL
Intervention: Second administration of GRAd-COV2
Number of subjects: 917

Group type: EXPERIMENTAL
Intervention: GRAd-COV2
Number of subjects: 917

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 917

Group type: EXPERIMENTAL
Intervention: Two vaccine injections
Number of subjects: 917

Group type: COMPARATOR
Intervention: Two doses of placebo
Number of subjects: 917
Study: 37315571

Group type: EXPERIMENTAL
Intervention: 16,000 IU of vitamin A palmitate for 8 weeks (AMD group)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 16,000 IU of vitamin A palmitate for 8 weeks (RPD group)
Number of subjects: 12
Study: 37315579

Group type: EXPERIMENTAL
Intervention: CP-506 with single dose irradiation
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: CP-506 with fractionated irradiation
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: CP-506
Number of subjects: 2

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 2
Study: 37315583

Group type: EXPERIMENTAL
Intervention: Panitumumab combined with MMC-5FU-based chemoradiotherapy (CRT)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Panitumumab combined with MMC-5FU-based CRT
Number of subjects: 45
Study: 37315590

Group type: EXPERIMENTAL
Intervention: Vortioxetine (initiated at 5 mg/day, up-titrated to 10 mg/day at day 8, flexible dosing thereafter [5-20 mg/day])
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Vortioxetine
Number of subjects: 82
Study: 37315794

Group type: EXPERIMENTAL
Intervention: High light physical activity (≥760 counts/min)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sedentary activity (0-100 counts/min), low light activity (101-759 counts/min), moderate and vigorous activity (≥1952 counts/min)
Number of subjects: 50
Study: 37315879

Group type: EXPERIMENTAL
Intervention: Late gadolinium enhancement (LGE) cMRI
Number of subjects: 67

Group type: COMPARATOR
Intervention: Echocardiographic measurements
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Serum concentrations of NT-proBNP
Number of subjects: 67
Study: 37315924

Group type: EXPERIMENTAL
Intervention: Combined intervention of DHA-rich fish oil (1.1 g/d DHA and 0.4 g/d EPA) and cocoa flavanols (500 mg/d flavan-3-ols)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Combined intervention of DHA-rich fish oil and cocoa flavanols
Number of subjects: 259

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 259
Study: 37316145

Group type: EXPERIMENTAL
Intervention: CCTA unblinded group
Number of subjects: 219

Group type: COMPARATOR
Intervention: CCTA blinded group
Number of subjects: 219
Study: 37316162

Group type: EXPERIMENTAL
Intervention: Low LVEF (<55%)
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Normal LVEF (55%-65%)
Number of subjects: 734

Group type: COMPARATOR
Intervention: High LVEF (>65%)
Number of subjects: 734
Study: 37316163

Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg)
Number of subjects: 50
Study: 37316311

Group type: EXPERIMENTAL
Intervention: Exenatide as an adjunct to nicotine patches
Number of subjects: 216

Group type: COMPARATOR
Intervention: Nicotine patches
Number of subjects: 216
Study: 37316315

Group type: EXPERIMENTAL
Intervention: Active low-level laser (LLL) with glass ionomer sealant and fluoride toothpaste
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham low-level laser (LLL) with glass ionomer sealant and fluoride toothpaste
Number of subjects: 50
Study: 37316316

Group type: COMPARATOR
Intervention: Control participants (n=427)
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Cases (n=182)
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Overall study recruitment
Number of subjects: 609
Study: 37316318

Group type: EXPERIMENTAL
Intervention: Gamified mobile health application (iGAME) for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Education about the benefits of physical activity (Control)
Number of subjects: 0
Study: 37316690

Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg twice daily
Number of subjects: 4183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4183
Study: 37316692

Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg orally once daily
Number of subjects: 1350
Study: 37316728

Group type: EXPERIMENTAL
Intervention: Isatuximab plus bortezomib, lenalidomide, and dexamethasone (Isa-VRd)
Number of subjects: 73
Study: 37316784

Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine + oxaliplatin
Number of subjects: 0
Study: 37316785

Group type: EXPERIMENTAL
Intervention: Days alive without life support (DAWOLS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complex regression models (hurdle-negative binomial, zero-one-inflated beta, cumulative logistic regression)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complex models
Number of subjects: 0
Study: 37316789

Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regional Anesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of General Anesthesia and Regional Anesthesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Induction Phase of Anesthesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Critical Incidents
Number of subjects: 0
Study: 37316843

Group type: EXPERIMENTAL
Intervention: Process improvement (text messages)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Barrier elicitation and reduction (electronic survey with tailored questions/prompts)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Teachable moment messaging (motivational interviewing)
Number of subjects: 0
Study: 37316847

Group type: EXPERIMENTAL
Intervention: Dapagliflozin therapy
Number of subjects: 2990
Study: 37316885

Group type: EXPERIMENTAL
Intervention: Closed-loop automated oxygen control (CLAC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Manual oxygen control
Number of subjects: 40
Study: 37316919

Group type: EXPERIMENTAL
Intervention: Continuous monitoring with a wearable sensor (heart rate, respiratory rate, posture, and activity) for 14 days
Number of subjects: 800

Group type: COMPARATOR
Intervention: Usual care without continuous monitoring
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Continuous monitoring
Number of subjects: 800
Study: 37317022

Group type: EXPERIMENTAL
Intervention: guselkumab 200 mg SC every 4 weeks through Week 36
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: guselkumab 1200 mg IV for 12 weeks, then switched to guselkumab 200 mg SC every 4 weeks from Weeks 12 through 36
Number of subjects: 100

Group type: COMPARATOR
Intervention: placebo for 12 weeks, then re-randomized to guselkumab 200 mg SC every 4 weeks or guselkumab 100 mg SC at specified weeks
Number of subjects: 100
Study: 37317676

Group type: EXPERIMENTAL
Intervention: Customizable educational brochure
Number of subjects: 165

Group type: COMPARATOR
Intervention: Standard educational brochure
Number of subjects: 165
Study: 37317838

Group type: EXPERIMENTAL
Intervention: Unilaterally selective adrenal vein sampling
Number of subjects: 1625

Group type: COMPARATOR
Intervention: RASI values ≤0.96 and >2.55 in patients without unilateral primary aldosteronism
Number of subjects: 1625
Study: 37317841

Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Number of subjects: 43
Study: 37317866

Group type: EXPERIMENTAL
Intervention: Radiofrequency renal denervation (RDN)
Number of subjects: 2746
Study: 37317993

Group type: EXPERIMENTAL
Intervention: Buparlisib (BKM120) monotherapy
Number of subjects: 4
Study: 37318023

Group type: EXPERIMENTAL
Intervention: Conventional balloon angioplasty
Number of subjects: 2895

Group type: EXPERIMENTAL
Intervention: Major adverse limb events (composite of all-cause death, target limb revascularization, or major amputation)
Number of subjects: 2895
Study: 37318085

Group type: EXPERIMENTAL
Intervention: Avatrombopag (AVA) at a starting dose of 20 mg/d, titrated to a maximum of 60 mg/d
Number of subjects: 25
Study: 37318116

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA)
Number of subjects: 4978

Group type: EXPERIMENTAL
Intervention: ICS/LABA + long-acting muscarinic antagonist (LAMA)
Number of subjects: 4978

Group type: EXPERIMENTAL
Intervention: LAMA monotherapy
Number of subjects: 4978

Group type: EXPERIMENTAL
Intervention: Long-acting inhalers
Number of subjects: 4978

Group type: EXPERIMENTAL
Intervention: ICS-containing therapy
Number of subjects: 4978

Group type: EXPERIMENTAL
Intervention: COPD assessment test score
Number of subjects: 4978

Group type: EXPERIMENTAL
Intervention: Exacerbation rates
Number of subjects: 4978

Group type: EXPERIMENTAL
Intervention: Exacerbation requiring hospitalization/emergency visit
Number of subjects: 4978

Group type: EXPERIMENTAL
Intervention: Adherence for long-acting inhalers
Number of subjects: 4978

Group type: EXPERIMENTAL
Intervention: COPD questionnaire score
Number of subjects: 4978
Study: 37318140

Group type: EXPERIMENTAL
Intervention: Mild hypercapnia (target Paco2 not specified) for 24 hours
Number of subjects: 1700

Group type: COMPARATOR
Intervention: Normocapnia (target Paco2 not specified) for 24 hours
Number of subjects: 1700
Study: 37318215

Group type: EXPERIMENTAL
Intervention: Machine learning model for classifying tympanometry tracings acquired by layperson
Number of subjects: 1635

Group type: COMPARATOR
Intervention: Tympanometer's built-in classifier
Number of subjects: 1635

Group type: COMPARATOR
Intervention: Decision tree based on clinically recommended normative values
Number of subjects: 1635

Group type: EXPERIMENTAL
Intervention: Machine learning model for classifying tympanometry tracings acquired by audiologist
Number of subjects: 1635
Study: 37318279

Group type: EXPERIMENTAL
Intervention: Perioperative behavioral and pelvic floor muscle training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 37318349

Group type: EXPERIMENTAL
Intervention: Talazoparib 1 mg once daily for 24 weeks
Number of subjects: 61
Study: 37318379

Group type: EXPERIMENTAL
Intervention: Tucatinib in combination with Trastuzumab
Number of subjects: 84
Study: 37318415

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 194

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 194

Group type: COMPARATOR
Intervention: Ranibizumab
Number of subjects: 194
Study: 37318419

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 4269

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4269
Study: 37318428

Group type: EXPERIMENTAL
Intervention: OPEN
Number of subjects: 1746

Group type: COMPARATOR
Intervention: ENDO
Number of subjects: 1746
Study: 37318469

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine infiltration along the nephrostomy tract (20 mL)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no bupivacaine infiltration)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine infiltration
Number of subjects: 50
Study: 37318549

Group type: EXPERIMENTAL
Intervention: Post-stroke fatigue (PSF) assessed using the Swedish version of the Fatigue Assessment Scale (S-FAS), defined as S-FAS score ≥ 24.
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: High body mass index (BMI) as a predictor of PSF.
Number of subjects: 305
Study: 37318580

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (IG)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard diet (CG)
Number of subjects: 68
Study: 37318673

Group type: EXPERIMENTAL
Intervention: Retinal artery diameter measurement using optical coherence tomography-angiography (OCT-A)
Number of subjects: 77
Study: 37318685

Group type: EXPERIMENTAL
Intervention: Sotagliflozin for 6 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 100
Study: 37318707

Group type: EXPERIMENTAL
Intervention: LipiFlow treatment prior to cataract surgery
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (no LipiFlow treatment prior to surgery)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group after crossover (received LipiFlow treatment)
Number of subjects: 121
Study: 37318750

Group type: EXPERIMENTAL
Intervention: Lebrikizumab 250 mg Q2W
Number of subjects: 206
Study: 37318803

Group type: EXPERIMENTAL
Intervention: 6-month PrEP dispensing with semiannual clinic visits and interim HIV self-testing at 3 months
Number of subjects: 495

Group type: COMPARATOR
Intervention: Standard-of-care (SOC) PrEP delivery with 3-month dispensing and quarterly clinic visits
Number of subjects: 495
Study: 37318808

Group type: EXPERIMENTAL
Intervention: Escitalopram, Sertraline, or Venlafaxine extended-release (1:1:1 randomization)
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Cognitive biotype positive subgroup
Number of subjects: 1008
Study: 37318865

Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation Facebook Intervention (Chat)
Number of subjects: 22
Study: 37318875

Group type: EXPERIMENTAL
Intervention: Audit, feedback, and education intervention (web-based surgical performance feedback dashboard)
Number of subjects: 15000

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 15000

Group type: EXPERIMENTAL
Intervention: Audit, feedback, and education intervention
Number of subjects: 15000